Background: Oncolytic viruses are promising cancer immunotherapies but questions have been raised regarding their safety. Pelareorep (REOLYSIN, R), an unmodified Reovirus Dearing strain, selectively replicates and lyses cancer cells and induces anti-tumor immunity. To date, 900+ patients (pts) have been treated with intravenous (IV) pelareorep. In a phase 2 trial, its combination with paclitaxel improved overall survival (17.4m) vs paclitaxel (10.4m) in metastatic breast cancer (MBC) pts (HR 0.65, 80% CI 0.46-0.91, p = 0.1; Berstein et.al. AACR2017). A pooled analysis was thus conducted to better characterize pelareorep’s safety profile in combinations with paclitaxel.